about
Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.Antifungal susceptibility testing: current role from the clinical laboratory perspectiveFlucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalClinical perspectives on echinocandin resistance among Candida speciesEpidemiology of invasive candidiasis: a persistent public health problemCandida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance programCandida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazoleData mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility TestingEvaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid)Correcting a Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility TestingAntifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitisCorrelation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcomeInterpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingResults obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosisFKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicansWhen does 2 plus 2 equal 5? A review of antimicrobial synergy testing.Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance programResistance patterns and clinical significance of Candida colonization and infection in combat-related injured patients from iraq and afghanistan.Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazoleAssociation of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agentsCross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida sppClinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Treatment outcomes of secondarily impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics.Anidulafungin: an echinocandin antifungal.Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testRecent advances in antifungal pharmacotherapy for invasive fungal infections.Combination treatment of invasive fungal infections.
P2860
Q24537282-1F053763-7AEE-486F-A280-FF50482709F8Q26862478-6FA8883A-F3BA-456B-B7AB-F5BD7304F249Q27012487-3E1BC4E5-E2FE-4AF3-8D2F-63D5F1FBE9BCQ28082538-367046F4-BBAA-48CF-9507-B3B9373D3C82Q29616758-BDB6F2F8-40A4-4F5A-834E-D2198FB6DB25Q30445376-D50CB29B-D1DC-407C-AE87-9BA4D6BEEDDDQ30445379-16309191-D094-4DAC-BE59-2AF3C883CDC5Q30452376-56683685-B601-4286-9D01-922B55837F70Q30452973-2382B7D4-C080-4526-8851-41F48FA759C1Q33443651-5A86E6F8-96CB-4554-BB4B-9D47D1FEEC71Q33528384-17118754-84BE-467C-8495-6F0EE088513BQ33556039-A57D9E22-99B3-4476-A2A5-2D2C34FF22B3Q33719218-30D2C66A-09F5-4778-ACB8-A06201CC3480Q33817871-549E2B58-8E1E-4407-B10A-BB7A2D1AFD42Q33859133-C13898D2-B5BC-4D67-9638-6D454BB2E37DQ33938082-9A91333F-CD93-44FE-9E65-07B3B11A6E3BQ33938166-CD89FB65-205B-4499-90EA-4A222CB9ADCDQ34005900-11D964D1-BAD8-4BBE-8188-39B53AC0763EQ34059670-8D21CC08-2B08-4EA2-8DD8-13E0E1ED3758Q34431984-DB789401-2193-4BB8-A670-98A019A2F189Q34510359-F4DDE532-567B-45E1-9FBE-E0F2853C2A1AQ34647337-F662CEC4-1B2F-4ECB-BFB9-16D8E8003377Q34721673-36863AE4-5568-42A3-8065-3AF7EABEF8ABQ34737334-D47AC22B-3ECC-4048-AC0F-50C0D66B6B62Q34923233-B1FA81BB-13AB-4276-A338-604D0BB2BC60Q35036156-FEA3082B-8633-480E-AED3-718BAABD8B0CQ35067016-4C939087-B12E-4256-90B3-35DA4D94071BQ35072030-2D45A18A-4E2D-41F7-BF3B-E81014D28DF5Q35552662-9B018F6D-FA3E-49D1-882C-11BCC3B08B38Q35635693-F35512F4-8B92-419B-BAD0-E69829046086Q35690629-817DAC95-2E23-4E7D-99A7-149C8CCA246CQ35714264-2B457847-365F-4C70-9487-D5963E405D86Q35738800-89064450-2DFF-4B90-9651-15BC1D27B9E5Q35745822-7F5B5888-EF5E-4919-8FC0-EF39BE61D3A3Q35846347-31373598-CB1B-459B-8E13-F280BFCD7025Q35871936-310220B4-99B2-4797-A2B0-9832368592EBQ35906882-AE8763D4-29B9-498B-8CF7-0782C287B7C1Q35913918-B8456C7F-D1E6-414F-A10D-8E5ED4B29AE8Q35917383-C354E0D4-1757-4A19-A193-7BBEC02993A4Q36011378-CF9BEB49-02B8-43BB-943D-3E1DCC7C8F7A
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Has antifungal susceptibility testing come of age?
@ast
Has antifungal susceptibility testing come of age?
@en
Has antifungal susceptibility testing come of age?
@nl
type
label
Has antifungal susceptibility testing come of age?
@ast
Has antifungal susceptibility testing come of age?
@en
Has antifungal susceptibility testing come of age?
@nl
prefLabel
Has antifungal susceptibility testing come of age?
@ast
Has antifungal susceptibility testing come of age?
@en
Has antifungal susceptibility testing come of age?
@nl
P2860
P356
P1476
Has antifungal susceptibility testing come of age?
@en
P2093
John H Rex
P2860
P304
P356
10.1086/342384
P407
P577
2002-09-24T00:00:00Z